USPTO Examiner STONEBRAKER ALYSSA RAE - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18923463POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDESOctober 2024December 2024Allow100NoNo
18456262ANTI-SEZ6 ANTIBODY DRUG CONJUGATESAugust 2023July 2024Allow1020NoNo
18546413PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODSAugust 2023July 2024Allow1211NoNo
18348948ENGINEERED NUCLEASES, COMPOSITIONS, AND METHODS OF USE THEREOFJuly 2023March 2024Allow911NoNo
18185805COMPOSITION AND METHOD OF USE RECOMBINANT FUSION PROTEIN TO GENERATE CAR-IMMUNE CELLSMarch 2023February 2024Allow1110YesNo
18043723USE OF VITELLOGENIN FOR DEFINING AND TESTING NOVEL IMMUNOGENS IN INSECTSMarch 2023July 2024Allow1711NoNo
18054018CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETYNovember 2022June 2025Abandon3231NoNo
17817754HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIESAugust 2022October 2023Allow1501YesNo
17877083PHOSPHINE-MEDIATED AMINE-AZIDE COUPLING IN IONIC LIQUID FOR BIOCONJUGATION REACTIONSJuly 2022June 2024Abandon2211YesNo
17874711ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45July 2022September 2024Allow2611YesNo
17854735MULTIVALENT ANTI-SARS-COV-2 NANOBODIESJune 2022April 2024Allow2121YesNo
17836517ANTIBODIES TARGETING AN AMPHIREGULIN-DERIVED CELL SURFACE NEO-EPITOPEJune 2022March 2024Allow2120YesNo
17836480COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATESJune 2022November 2023Allow1710NoNo
17832093DOSING OF A BISPECIFIC ANTIBODY THAT BINDS CD20 AND CD3June 2022January 2024Allow1910NoNo
17829671TUMOR CELL VACCINESJune 2022January 2025Abandon3211NoNo
17828740ANTI-NKG2A ANTIBODIES AND COMPOSITIONSMay 2022February 2024Allow2011YesNo
17727628COMPOSITIONS AND METHODS FOR TREATMENT OF INVASIVE CANCERSApril 2022April 2024Allow2430YesNo
17690968IMMUNE CELL FUNCTIONMarch 2022April 2025Allow3721YesNo
17582355METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITYJanuary 2022January 2024Allow2410NoNo
17554557Rocky Mountain Spotted Fever Detection and TreatmentDecember 2021October 2024Allow3421YesNo
17517535COMPOSITIONS AND METHODS EMPLOYING ADENOSINE DEAMINASE-1 (ADA-1) AS AN ADJUVANTNovember 2021April 2024Allow2911NoNo
17516601SAP FC FUSION PROTEINS AND METHODS OF USENovember 2021October 2024Allow3521NoNo
17516259BREAST CANCER TUMOR CELL VACCINESNovember 2021December 2024Abandon3811NoNo
17516203COLORECTAL CANCER TUMOR CELL VACCINESNovember 2021December 2024Abandon3811NoNo
17512071FLOW CYTOMETRIC METHOD FOR CHARACTERIZATION OF T-CELL IMPURITIESOctober 2021June 2024Abandon3211NoNo
17499444BIOMARKERS FOR DETERMINING SURVIVAL AND THERAPEUTIC RESPONSE IN CERVICAL CANCEROctober 2021March 2024Abandon2901NoNo
17295225OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOFSeptember 2021May 2025Abandon4801NoNo
17433780FORMULATION COMPRISING ANTI-CD47 ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOFAugust 2021June 2025Abandon4610NoNo
17409462SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCSAugust 2021October 2024Allow3810NoNo
17427301ANTI-FGF19 ANTIBODIESJuly 2021June 2025Allow4611YesNo
17427117SIGNALING PLATFORMS FOR CHIMERIC ANTIGEN RECEPTOR T CELLSJuly 2021February 2025Abandon4301NoNo
17426723BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB FOR TREATING CANCERJuly 2021April 2025Abandon4410NoNo
17420987ANTI-TIGIT ANTIBODIESJuly 2021January 2025Allow4310YesNo
17413456METHOD OF TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES USING B CELLSJune 2021April 2025Allow4611YesNo
17311619HUMAN ANTI-ANTXR CHIMERIC ANTIGEN RECEPTOR AND USE THEREOFJune 2021March 2025Allow4621YesNo
17295896AN ANTI-B7-H3 ANTIBODYMay 2021September 2024Allow4010YesNo
17295603ANTIBODY AND USE THEREOFMay 2021January 2025Allow4411YesNo
17295773ANTI-TNFR2 ANTIBODY AND USE THEREOFMay 2021January 2025Allow4411YesNo
17295394ANTI-PD-L1/VEGF BIFUNCTIONAL ANTIBODY AND USE THEREOFMay 2021December 2024Allow4311YesNo
17320891ALS Treatment Using Induced Regulatory T (iTREG) CellsMay 2021September 2024Allow4011NoNo
17320125CD25 ANTIBODIESMay 2021October 2024Allow4211YesNo
17289058DC-SIGN ANTIBODY DRUG CONJUGATESApril 2021January 2025Abandon4501NoNo
17285303METHODS AND COMPOSITIONS FOR TREATING TAUOPATHIESApril 2021August 2024Abandon4001NoNo
17280726DUAL TARGETING ANTIGEN BINDING MOLECULEMarch 2021October 2024Abandon4210NoNo
17280537METHODS OF TREATING INFLAMMATIONMarch 2021April 2025Abandon4920NoNo
17274858ADMINISTRATION OF AN ANTI-C5 AGENT FOR TREATMENT OF HEPATIC INJURY OR FAILUREMarch 2021September 2024Abandon4210NoNo
17274512METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD154 ANTIBODYMarch 2021September 2024Abandon4210NoNo
17272027MONOCLONAL ANTIBODY 14F5F6 OR FRAGMENT THEREOF, THAT SPECIFICALLY RECOGNIZES HERPES SIMPLEX VIRUS 1 AND 2February 2021November 2024Allow4411YesNo
17176841METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDEFebruary 2021August 2024Abandon4210NoNo
17267637ANTI-HUMAN CLAUDIN 18.2 MONOCLONAL ANTIBODY AND APPLICATION THEREOFFebruary 2021September 2024Allow4311NoNo
17164197COMPOSITIONS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTSFebruary 2021April 2025Allow5040NoNo
17262351NOVEL CLDN 18.2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOFJanuary 2021March 2024Allow3811YesNo
17154678METHOD FOR PURIFYING ANTIBODIESJanuary 2021March 2025Allow5020YesNo
17259910Use Of Liposomes To Deliver A Protein And A Gene Encoding The Protein To A Live CellJanuary 2021January 2025Abandon4821NoNo
17259634MESOTHELIN AND CD137 BINDING MOLECULESJanuary 2021January 2025Allow4811YesNo
17259642ANTIBODY MOLECULESJanuary 2021October 2024Allow4511NoNo
17259051COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTSJanuary 2021June 2024Abandon4101NoNo
17250353EFFICIENTLY EXPRESSED EGFR AND PD-L1 BISPECIFIC BINDING PROTEINSJanuary 2021August 2024Abandon4301NoNo
17051293Biosensors for Measuring Metastatic Potential and Chemoresistance of Single Cancer CellsOctober 2020May 2025Allow5431YesNo
17047134LYSATES OF RECOMBINANT YEAST FOR INDUCING CELLULAR IMMUNE RESPONSESOctober 2020September 2024Allow4711NoNo
17046169METHODS OF TREATMENT FOR CANDIDA AURIS INFECTIONSOctober 2020February 2025Allow5230YesNo
17042032METHODS OF TREATING GLIOBLASTOMASSeptember 2020April 2024Allow4310YesNo
17027856General Sequence Of Chimeric Antigen Receptor, Chimeric Antigen Receptor And An Application ThereofSeptember 2020January 2024Allow3901YesNo
16976040COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPYAugust 2020April 2025Abandon5511NoNo
16999123METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIESAugust 2020November 2024Abandon5111NoNo
16966339CONSTRUCTION AND METHODS OF USE OF A BARCODED AND GENE EDITED DNA LIBRARYJuly 2020July 2024Allow4701YesNo
16919236USE OF CAPRYLIC ACID PRECIPITATION FOR PROTEIN PURIFICATIONJuly 2020October 2024Abandon5111NoNo
16955684FUSION PROTEINSJune 2020April 2024Abandon4631NoNo
16768617BINDING PROTEINS SPECIFIC FOR 5T4 AND USES THEREOFMay 2020May 2024Abandon4701NoNo
16881102USE OF ALKALINE WASHES DURING CHROMATOGRAPHY TO REMOVE IMPURITIESMay 2020July 2024Allow5020NoNo
16754877NETRIN G1 AS A BIOMARKER FOR ENHANCING TUMOR TREATMENT EFFICACYApril 2020May 2024Allow4941YesNo
16842864Methods of Controlling the Formation of Disulfide Bonds in Protein SolutionsApril 2020October 2024Abandon5411NoNo
16650415METHOD FOR CONFIRMING PRDM14 EXPRESSIONMarch 2020March 2024Abandon4801NoNo
16644544METHODS AND DEVICES FOR DETECTING BIOMARKERS ASSOCIATED WITH PREECLAMPSIAMarch 2020February 2024Abandon4801NoNo
15680080IMMUNOCONJUGATES FOR SPECIFIC INDUCTION OF T CELL CYTOTOXICITY AGAINST A TARGET CELLAugust 2017May 2024Abandon6071NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner STONEBRAKER, ALYSSA RAE - Prosecution Strategy Guide

Executive Summary

Examiner STONEBRAKER, ALYSSA RAE works in Art Unit 1642 and has examined 74 patent applications in our dataset. With an allowance rate of 59.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner STONEBRAKER, ALYSSA RAE's allowance rate of 59.5% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STONEBRAKER, ALYSSA RAE receive 1.27 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STONEBRAKER, ALYSSA RAE is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +61.0% benefit to allowance rate for applications examined by STONEBRAKER, ALYSSA RAE. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.